Thomas Gad Biography and Net Worth

Thomas Gad (Chairman) is Founder, President, and Head of Business Development and Strategy. Inspired by his daughter’s transformational and challenging journey through years of high-risk neuroblastoma treatment and her experience receiving breakthrough immunotherapy at Memorial Sloan Kettering Cancer Center (MSKCC) to overcome the cancer, Mr. Gad founded Y-mAbs Therapeutics, securing executive management and seed capital for the inception of the Company. Mr. Gad has more than 12 years of experience in the pharmaceutical industry, including business development, senior management, financing, and licensing negotiations. Mr. Gad has a Bachelor of Science degree in Business Administration from Pepperdine University, California, US.

What is Thomas Gad's net worth?

The estimated net worth of Thomas Gad is at least $4.01 million as of December 15th, 2023. Mr. Gad owns 265,032 shares of Y-mAbs Therapeutics stock worth more than $4,012,584 as of April 16th. This net worth approximation does not reflect any other assets that Mr. Gad may own. Additionally, Mr. Gad receives an annual salary of $1,050,000.00 as Insider at Y-mAbs Therapeutics. Learn More about Thomas Gad's net worth.

How old is Thomas Gad?

Mr. Gad is currently 53 years old. There are 5 older executives and no younger executives at Y-mAbs Therapeutics. Learn More on Thomas Gad's age.

What is Thomas Gad's salary?

As the Insider of Y-mAbs Therapeutics, Inc., Mr. Gad earns $1,050,000.00 per year. Learn More on Thomas Gad's salary.

How do I contact Thomas Gad?

The corporate mailing address for Mr. Gad and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Thomas Gad's contact information.

Has Thomas Gad been buying or selling shares of Y-mAbs Therapeutics?

Thomas Gad has not been actively trading shares of Y-mAbs Therapeutics within the last three months. Most recently, Thomas Gad sold 50,000 shares of the business's stock in a transaction on Friday, December 15th. The shares were sold at an average price of $6.61, for a transaction totalling $330,500.00. Following the completion of the sale, the insider now directly owns 265,032 shares of the company's stock, valued at $1,751,861.52. Learn More on Thomas Gad's trading history.

Who are Y-mAbs Therapeutics' active insiders?

Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), and Johan Wedell-Wedellsborg (Director). Learn More on Y-mAbs Therapeutics' active insiders.

Are insiders buying or selling shares of Y-mAbs Therapeutics?

During the last twelve months, Y-mAbs Therapeutics insiders bought shares 5 times. They purchased a total of 325,139 shares worth more than $2,395,729.86. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 176,711 shares worth more than $1,085,282.83. The most recent insider tranaction occured on March, 5th when SVP Vignesh Rajah sold 1,711 shares worth more than $28,282.83. Insiders at Y-mAbs Therapeutics own 21.5% of the company. Learn More about insider trades at Y-mAbs Therapeutics.

Information on this page was last updated on 3/5/2024.

Thomas Gad Insider Trading History at Y-mAbs Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2023Sell50,000$6.61$330,500.00265,032View SEC Filing Icon  
12/13/2023Sell50,000$6.58$329,000.00365,032View SEC Filing Icon  
11/20/2023Sell75,000$5.30$397,500.00490,032View SEC Filing Icon  
2/9/2022Sell64,276$6.96$447,360.96View SEC Filing Icon  
2/7/2022Sell91,031$7.59$690,925.29View SEC Filing Icon  
2/3/2022Sell35,060$7.90$276,974.00View SEC Filing Icon  
2/1/2022Sell8,000$10.15$81,200.00View SEC Filing Icon  
1/24/2022Sell88,055$10.63$936,024.65View SEC Filing Icon  
1/20/2022Sell112,767$11.33$1,277,650.11View SEC Filing Icon  
1/18/2022Sell8,000$11.54$92,320.00View SEC Filing Icon  
12/6/2021Sell44,000$16.48$725,120.00View SEC Filing Icon  
11/29/2021Sell22,437$17.16$385,018.92View SEC Filing Icon  
11/23/2021Sell50,000$17.06$853,000.00View SEC Filing Icon  
11/16/2021Sell4,000$19.33$77,320.00View SEC Filing Icon  
10/29/2021Sell4,000$24.82$99,280.00View SEC Filing Icon  
10/15/2021Sell4,000$27.20$108,800.00View SEC Filing Icon  
9/30/2021Sell4,000$28.26$113,040.00View SEC Filing Icon  
9/15/2021Sell4,000$33.64$134,560.00View SEC Filing Icon  
9/2/2021Sell50,000$33.18$1,659,000.0050,000View SEC Filing Icon  
8/16/2021Sell26,111$29.30$765,052.30View SEC Filing Icon  
8/13/2021Sell1,110$31.01$34,421.10View SEC Filing Icon  
7/20/2021Sell4,000$32.47$129,880.00View SEC Filing Icon  
6/14/2021Sell4,000$35.80$143,200.00View SEC Filing Icon  
5/28/2021Sell4,000$36.95$147,800.00View SEC Filing Icon  
4/26/2021Sell7,000$27.96$195,720.007,000View SEC Filing Icon  
4/12/2021Sell7,000$26.61$186,270.007,000View SEC Filing Icon  
3/15/2021Sell7,000$36.79$257,530.007,000View SEC Filing Icon  
1/19/2021Sell7,000$46.51$325,570.007,000View SEC Filing Icon  
1/5/2021Sell7,000$49.36$345,520.007,000View SEC Filing Icon  
12/28/2020Sell7,000$51.98$363,860.007,000View SEC Filing Icon  
12/16/2020Sell7,000$53.01$371,070.007,000View SEC Filing Icon  
12/14/2020Sell4,000$52.89$211,560.00View SEC Filing Icon  
12/10/2020Sell50,000$50.75$2,537,500.0050,000View SEC Filing Icon  
12/1/2020Sell4,000$51.42$205,680.00View SEC Filing Icon  
10/15/2020Sell4,000$39.15$156,600.00View SEC Filing Icon  
10/1/2020Sell4,000$38.88$155,520.00View SEC Filing Icon  
9/14/2020Sell22,569$41.00$925,329.0013,860View SEC Filing Icon  
9/11/2020Sell13,571$40.33$547,318.4313,860View SEC Filing Icon  
9/1/2020Sell4,000$41.60$166,400.00View SEC Filing Icon  
8/17/2020Sell4,000$40.35$161,400.00View SEC Filing Icon  
8/11/2020Sell37,000$40.06$1,482,220.00View SEC Filing Icon  
7/15/2020Sell4,000$40.06$160,240.00View SEC Filing Icon  
6/15/2020Sell4,000$43.45$173,800.00View SEC Filing Icon  
6/4/2020Sell4,000$41.61$166,440.00View SEC Filing Icon  
5/12/2020Sell50,000$39.04$1,952,000.00View SEC Filing Icon  
4/13/2020Sell4,000$29.43$117,720.00View SEC Filing Icon  
3/16/2020Sell4,000$18.01$72,040.00View SEC Filing Icon  
2/10/2020Sell4,000$33.03$132,120.00View SEC Filing Icon  
1/27/2020Sell4,000$35.06$140,240.00View SEC Filing Icon  
1/13/2020Sell4,000$30.90$123,600.00View SEC Filing Icon  
12/16/2019Sell4,000$31.54$126,160.00View SEC Filing Icon  
12/2/2019Sell4,000$32.48$129,920.00View SEC Filing Icon  
9/3/2019Sell4,000$25.77$103,080.00View SEC Filing Icon  
8/19/2019Sell4,000$27.70$110,800.00View SEC Filing Icon  
8/5/2019Sell4,000$21.78$87,120.00View SEC Filing Icon  
7/22/2019Sell4,000$22.54$90,160.00View SEC Filing Icon  
7/8/2019Sell4,000$22.40$89,600.00View SEC Filing Icon  
6/24/2019Sell4,000$21.77$87,080.00View SEC Filing Icon  
6/10/2019Sell4,000$22.79$91,160.00View SEC Filing Icon  
6/3/2019Sell4,000$20.03$80,120.00View SEC Filing Icon  
5/28/2019Sell6,000$20.21$121,260.00View SEC Filing Icon  
5/13/2019Sell6,000$20.61$123,660.00View SEC Filing Icon  
4/11/2019Sell250,000$25.89$6,472,500.00View SEC Filing Icon  
See Full Table

Thomas Gad Buying and Selling Activity at Y-mAbs Therapeutics

This chart shows Thomas Gad's buying and selling at Y-mAbs Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $15.14
Low: $14.50
High: $15.69

50 Day Range

MA: $15.61
Low: $12.97
High: $18.69

2 Week Range

Now: $15.14
Low: $4.60
High: $20.90


442,474 shs

Average Volume

401,450 shs

Market Capitalization

$662.83 million

P/E Ratio


Dividend Yield